Author Archive

Low vitamin D levels may be associated with more advanced physical disability and cognitive impairment in persons with multiple sclerosis, studies conducted by neurologists at the University at Buffalo have shown…

An Australian study published today (Friday 30 April) has shed further light on the correlation between vitamin D and MS. The study, published in the British Medical Journal, shows that people born after the vitamin D-scarce winter months are roughly 30% more likely to go on to develop MS later in life compared with those born after the summer months…

Scientists are reporting what they say is compelling evidence that some powerful non-heritable, environmental factor likely plays a key role in the development of multiple sclerosis…

Hospital for Special Care announced the launch of the region’s first Amyotrophic Lateral Sclerosis (ALS) Clinical Trials Unit at its Neuromuscular Center. The new unit will be headed by Jinsy A. Andrews, M.D., a physician researcher recruited from Columbia University. Dr…

A new Mayo Clinic study has found that the type of tissue damage changes throughout the course of multiple sclerosis (MS). In early relapsing disease stages, the plaques, or areas where the nervous system is inflamed or demyelinated, are predominantly active with distinct heterogeneous patterns of myelin damage…

The MS Society has made a number of significant appointments to its research advisory committees and steering groups in a step to ensure the charity’s research programme maximises its impact on the lives of people affected by MS…

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) have announced results from a one-year, longitudinal health outcomes study (n=324) in which patients with multiple sclerosis (MS) who received 12 infusions of TYSABRI (natalizumab) reported improvements in quality of life (QoL) measures, as well as reduced fatigue and overall improved cognitive function, as measur…

A UCSF-led study examining the impact of statins on the progression of multiple sclerosis found a lower incidence of new brain lesions in patients taking the cholesterol-lowering drug in the early stages of the disease as compared to a placebo. Study participants received an 80 milligram daily dose of atorvastatin, marketed by Pfizer Inc. as Lipitor…

Genzyme Corporation (Nasdaq: GENZ) reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an estimated 71 percent of alemtuzumab treated patients remain free of clinically-active disease as much as three years after most patients received their last course of the investigational compound…

Teva Neuroscience today announced results at the 62nd American Academy of Neurology Annual Meeting which demonstrated that eliminating barriers to neutralizing antibodies (NAbs) testing significantly impacted multiple sclerosis (MS) treatment choices in patients receiving interferon beta (IFNβ) therapies…